echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jingfeng Pharmaceutical's gemcitabine hydrochloride for injection passed the consistency evaluation of generic drugs

    Jingfeng Pharmaceutical's gemcitabine hydrochloride for injection passed the consistency evaluation of generic drugs

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 15, Jingfeng Pharmaceutical announced that its subsidiary Hainan Jinrui Pharmaceutical received the "Drug Supplementary Application Approval Notice" for gemcitabine hydrochloride for injection approved and issued by the State Food and Drug Administration.
    The subsidiary gemcitabine hydrochloride for injection passed the quality and quality of generic drugs.
    Consistency evaluation of efficacy
    .

    Gemcitabine hydrochloride for injection is mainly suitable for the treatment of locally advanced or metastatic non-small cell lung cancer or pancreatic cancer.
    It can also be combined with paclitaxel for the treatment of relapsed, unresectable, locally recurring or metastatic breast after adjuvant/neoadjuvant chemotherapy Cancer
    .


    The original research product was developed by Eli Lilly and is now a category B product in the National Medical Insurance Catalog


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.